DK452289A - Praeparat eller system til behandling af diabetes - Google Patents

Praeparat eller system til behandling af diabetes Download PDF

Info

Publication number
DK452289A
DK452289A DK452289A DK452289A DK452289A DK 452289 A DK452289 A DK 452289A DK 452289 A DK452289 A DK 452289A DK 452289 A DK452289 A DK 452289A DK 452289 A DK452289 A DK 452289A
Authority
DK
Denmark
Prior art keywords
insulin
function
liver
targeted
encapsulated
Prior art date
Application number
DK452289A
Other languages
Danish (da)
English (en)
Other versions
DK452289D0 (da
Inventor
Walter Blair Geho
Original Assignee
Technology Unlimited Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technology Unlimited Inc filed Critical Technology Unlimited Inc
Publication of DK452289D0 publication Critical patent/DK452289D0/da
Publication of DK452289A publication Critical patent/DK452289A/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Birds (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK452289A 1988-01-13 1989-09-13 Praeparat eller system til behandling af diabetes DK452289A (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/143,180 US4863896A (en) 1984-05-03 1988-01-13 Diabetic control by combined insulin forms
PCT/US1988/001536 WO1989006540A1 (fr) 1988-01-13 1988-05-13 Traitement du diabete par administration de deux formes d'insuline combinees

Publications (2)

Publication Number Publication Date
DK452289D0 DK452289D0 (da) 1989-09-13
DK452289A true DK452289A (da) 1989-11-09

Family

ID=22502938

Family Applications (1)

Application Number Title Priority Date Filing Date
DK452289A DK452289A (da) 1988-01-13 1989-09-13 Praeparat eller system til behandling af diabetes

Country Status (8)

Country Link
US (1) US4863896A (fr)
EP (1) EP0358709B1 (fr)
AT (1) ATE78169T1 (fr)
AU (1) AU622370B2 (fr)
DE (1) DE3872878T2 (fr)
DK (1) DK452289A (fr)
FI (1) FI894376A0 (fr)
WO (1) WO1989006540A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5420108A (en) * 1992-09-14 1995-05-30 Shohet; Isaac H. Method of controlling diabetes mellitus
WO1999016425A1 (fr) * 1997-09-30 1999-04-08 The Ohio State University Liposomes a insuline modifiee par lipides incorporee permettant de delivrer des agents cytotoxiques aux cellules d'un hepatome
US7169410B1 (en) * 1998-05-19 2007-01-30 Sdg, Inc. Targeted liposomal drug delivery system
US6159931A (en) * 1998-09-29 2000-12-12 The Ohio State University Lipid-modified insulin incorporated liposomes for selectively delivering cytotoxic agents to hepatoma cells
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7196059B2 (en) 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
WO2003105768A2 (fr) * 2002-06-13 2003-12-24 Nobex Corporation Methodes de reduction du nombre et de la gravite des episodes hypoglycemiques dans le traitement du diabete sucre
CA2511530C (fr) 2003-01-06 2013-07-09 Emisphere Technologies, Inc. Therapie d'administration orale d'insuline le soir
US20050203001A1 (en) 2004-03-05 2005-09-15 Emisphere Technologies, Inc. Oral insulin therapies and protocol
CA2536393A1 (fr) * 2003-09-09 2005-06-16 Gilead Sciences, Inc. Utilisation de liposomes, qui sont de petites vesicules monofeuillets, pour l'elimination d'une entite d'un echantillon biologique
CN105801686B (zh) 2004-07-19 2020-04-07 比奥孔有限公司 胰岛素-低聚物共轭物、制剂及其用途
US20110135725A1 (en) 2005-05-23 2011-06-09 Sdg, Inc. Lipid Construct for Delivery of Insulin to a Mammal
EP3391876B1 (fr) * 2005-05-23 2021-03-10 SDG, Inc. Construction lipidique pour administration d'insuline à un mammifère
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
EP2203181B1 (fr) 2007-10-16 2018-02-14 Biocon Limited Composition pharmaceutique solide administrable par voie orale et procédé associé
US20120035105A1 (en) * 2009-01-09 2012-02-09 Sdg, Inc. Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments
US8846103B2 (en) 2009-01-28 2014-09-30 Smartcells, Inc. Exogenously triggered controlled release materials and uses thereof
CA2750269A1 (fr) 2009-01-28 2010-08-05 Smartcells, Inc. Conjugues d'insuline cristalline
CA2750252A1 (fr) 2009-01-28 2010-08-05 Smartcells, Inc. Conjugues synthetiques et leurs utilisations
WO2010088294A1 (fr) 2009-01-28 2010-08-05 Smartcells, Inc. Systèmes à base de conjugués pour administration contrôlée de médicaments
AU2010226243A1 (en) 2009-03-20 2011-09-22 Smartcells, Inc. Terminally-functionalized conjugates and uses thereof
US8569231B2 (en) 2009-03-20 2013-10-29 Smartcells, Inc. Soluble non-depot insulin conjugates and uses thereof
JP2013535467A (ja) 2010-07-28 2013-09-12 スマートセルズ・インコーポレイテツド 組換えにより発現されたインスリンポリペプチドおよびその使用
EP2598170A4 (fr) 2010-07-28 2016-07-06 Smartcells Inc Conjugués médicaments-ligands, leur synthèse et intermédiaires correspondants
JP2013541500A (ja) 2010-07-28 2013-11-14 スマートセルズ・インコーポレイテツド 組換えレクチン、結合部位修飾レクチンおよびそれらの用途
AU2014329567B2 (en) 2013-10-04 2019-07-25 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
US11077173B2 (en) 2017-03-13 2021-08-03 Sdg, Inc. Lipid-based nanoparticles and methods using same
KR20190124269A (ko) 2017-03-13 2019-11-04 에스디지,인코포레이티드 안정성이 증진된 지질 기반 나노입자
AU2020271901A1 (en) * 2019-04-12 2021-11-04 Sdg, Inc. Lipid-based nanoparticles and use of same in optimized insulin dosing regimens

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4377567A (en) * 1978-10-02 1983-03-22 The Procter & Gamble Company Lipid membrane drug delivery
US4603044A (en) * 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system

Also Published As

Publication number Publication date
EP0358709A4 (fr) 1990-03-08
DE3872878T2 (de) 1992-12-03
AU1790588A (en) 1989-08-11
EP0358709A1 (fr) 1990-03-21
WO1989006540A1 (fr) 1989-07-27
AU622370B2 (en) 1992-04-02
EP0358709B1 (fr) 1992-07-15
DE3872878D1 (de) 1992-08-20
DK452289D0 (da) 1989-09-13
US4863896A (en) 1989-09-05
ATE78169T1 (de) 1992-08-15
FI894376A0 (fi) 1989-09-15

Similar Documents

Publication Publication Date Title
DK452289A (da) Praeparat eller system til behandling af diabetes
DK0527835T3 (da) Doseringsform til afgivelse af et anti-Parkinsonmiddel
DK0480934T3 (da) Lægemiddel, der indeholder ephedrin og koffein til behandling af overvægt
FI875533A (fi) Insulinpreparat foer non-parenteral dosering.
FI880409A (fi) Transdermalt absorberande doseringsenhet foer estradiol och andra estrogena steroider och administrationsfoerfarande.
SE9401406L (sv) Farmaceutiska produkter för att bota tumörsjukdomar samt förfarande för framställning av desamma
ATE96308T1 (de) Dosierform fuer verabreichung in der humanmedizin.
DE59808186D1 (de) Transdermales therapeutisches system zur abgabe von hormonen
SE8204874L (sv) Farmaceutiska preparat, innefattande humant insulin och humant proinsulin
ES2107511T3 (es) Procedimiento para la preparacion de un concentrado de factor xi de la coagulacion sanguinea con alta actividad especifica, apropiado para su uso terapeutico.
KR910005858A (ko) 지방산 요법
AR003979A1 (es) Administracion transdermica de vorozol.
KR100271087B1 (en) Protein synthesis stimulator comprising tcf-2 for the treatment of hypoproteinemia
KR870010871A (ko) 재조합 인체 알파 인터페론에 의한 기저세포 암종의 병소내적 치료방법
EA199800770A1 (ru) Лекарственный препарат для терапевтического лечения вирусного гепатита
DK1007085T3 (da) Anvendelse af væksthormon i præparater til behandling af insulin-resistens i hjertet
SE9101341D0 (sv) New medicinal use
Kobrine et al. Further studies on histamine in spinal cord injury and post traumatic hyperemia
GB2019720A (en) S-adenosyl-L-homocysteine and salts thereof for use in therapy
徐济民 et al. ANTIARRHYTHMIC ACTION OF CHANGROLIN ADMINISTERED BY CONTINUOUS INTRAVENOUS INFUSION
黄涛生 et al. Changes in Protein Metabolism of Soleus Muscle in Scalded Rats and the Therapeutic Effects of Leucine and Insulin
施炳培 et al. THE RADIATION OF THE HE-NE LASER ON ACUPOINTS IN TREATMENT OF INFANTILE CHRONIC DIARRHEA IN 93 CASES
RU94006632A (ru) Способ лечения неспецифического язвенного колита
KR920007624A (ko) 단백질 의약품의 경구투여용 조성물
ES256653U (es) Prenda terapeutica perfeccionada

Legal Events

Date Code Title Description
AHS Application shelved for other reasons than non-payment